FDA to fast-track review of three psychedelic therapies for depression and PTSD

The FDA announced it will accelerate the review of psychedelic drugs from three companies as part of a broader initiative to increase access to mental-health treatments.

Compass Pathways will receive a priority review voucher for its psilocybin candidate aimed at treatment-resistant depression. Usona Institute's similar psilocybin product for major depressive disorder also qualifies for the voucher.

Transcend Therapeutics will get a voucher for its MDMA-like therapy targeting post-traumatic stress disorder. The accelerated timelines are intended to bring these experimental therapies to patients more quickly.

The move reflects the current administration's emphasis on expanding options for mental-health care, though the drugs remain under investigation and have not yet received approval.